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Abstract
The standardized techniques of blood pressure (BP) measurement in the clinic are emphasized and it is
recommended to replace the mercury sphygmomanometer by a non-mercury sphygmomanometer. Out-of-office
BP measurement using home BP monitoring (HBPM) or ambulatory BP monitoring (ABPM) and even automated
office BP (AOBP) are recommended to correctly measure the patient’s genuine BP. Hypertension (HTN) treatment
should be individualized based on cardiovascular (CV) risk and the level of BP. Based on the recent clinical study
data proving benefits of intensive BP lowering in the high risk patients, the revised guideline recommends the
more intensive BP lowering in high risk patients including the elderly population. Lifestyle modifications, mostly low
salt diet and weight reduction, are strongly recommended in the population with elevated BP and prehypertension
and all hypertensive patients. In patients with BP higher than 160/100 mmHg or more than 20/10 mmHg above the
target BP, two drugs can be prescribed in combination to maximize the antihypertensive effect and to achieve
rapid BP control. Especially, single pill combination drugs have multiple benefits, including maximizing reduction of
BP, minimizing adverse effects, increasing adherence, and preventing cardiovascular disease (CVD) and target organ
damage.
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These Korean Society of Hypertension guidelines for the
management of hypertension defined levels of evidence
as below: A, Data derived from multiple randomized
controlled trials or meta-analysis; B, Data derived from a
single randomized controlled trials or non-randomized
clinical trials; C, Experts’ opinion or data derived from
limited evidences. Also classes f recommendations were
defined as below: Class I, Evidence and/or general agree-
ment that a given treatment or procedure is beneficial,
useful, and effective. Therefore it should be performed;
Class IIa, Conflicting evidence and/or a divergence of
opinion about the usefulness/efficacy of the given
treatment or procedure exists. However, in general,
weight of evidence/opinion is in favor of usefulness/effi-
cacy. Therefore it is reasonable to be performed; Class
IIb, Usefulness/efficacy is less well established by evi-
dence/opinion. Therefore it may be considered; Class III,
Evidence or general agreement that the given treatment
or procedure is not beneficial and in some cases may be
harmful. Therefore it is not recommended.
Chapter I. clinical evaluation
Blood pressure measurement
Accurate measurement of BP is essential for the diagno-
sis, treatment, and prognostication of individuals with
high BP. BP varies according to the environment, body
part, and clinical setting of measurement. Therefore, the
measurement should be repeated and a standard method
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: scchae@knu.ac.kr
7Division of Cardiology, Department of Internal Medicine, Kyungpook
National University School of Medicine, Daegu, Korea
Full list of author information is available at the end of the article
Lee et al. Clinical Hypertension           (2019) 25:20 
https://doi.org/10.1186/s40885-019-0124-x
should be used (Table 1). All adults who are over 40
years old, obese, or have family history of HTN should
measure blood pressure annually. In patients with prehy-
pertension (130–139/80–89mmHg), BP should also be
measured annually.
Measurement of the office or clinic blood pressure
Recommendations Class Level References
• A mercury sphygmomanometer is
recommended to be replaced by a non-
mercury sphygmomanometer.
IIa C [1]
In the office or clinic, the auscultatory method of
measuring BP using a stethoscope is the current
standard measurement method. BP measuring devices
used for the office BP measurement include a mercury
sphygmomanometer, an aneroid sphygmomanometer,
and an electronic sphygmomanometer. Electronic
sphygmomanometers comprise auscultation and vibration
method equipment. The mercury sphygmomanometer
will be banned by 2020 because of the risk of
environmental mercury pollution. Recently, the non-
mercury sphygmomanometer equipped with various
electronic pressure gauges has been certified and is com-
mercially available so that BP can be measured by
auscultation or by the oscillometric method instead of by
mercury BP monitoring (http://www.dableducational.org).
For BP measurement based on the auscultation
method, the differences between mercury and non-
mercury sphygmomanometers are negligible and fur-
thermore, non-mercury sphygmomanometers are less
subject to observed eye-level error. However, oscillo-
metric method might be less accurate in the elderly,
pregnant women, children, or subjects with arrhythmia.
After the patient rests for five or more minutes, the BP
is measured by the auscultation method. The measure-
ment is reported two or more times (Table 1).
A cuff with an appropriately sized bladder should be
used. The standard bladder for adults is 13 cm wide and
22–24 cm long. The use of a bladder with a width of at
least 40% of the circumference of the arm and a length of
80–100% of the circumference of the arm is
recommended. A cuff of appropriate size as recommended
by the manufacturer should be used.
In the case of the automatic sphygmomanometers of
vibration method, a cuff of the size recommended in the
instruction manual should be used. A cuff that is too
small can produce an artificially high BP reading,
whereas a cuff that is too large can produce an
artificially low BP reading. If the pulses of the lower
extremities are weak, BP is measured in the legs to
exclude the possibility of peripheral arterial disease
(PAD). The upper arm cuff is applied to the ankle and
auscultation is performed on the dorsalis pedis or
posterior tibial artery. A large cuff can be applied to the
thigh, using a bladder that is 20% wider than the
diameter of the thigh (15–18 cm). Auscultation is
performed on the posterior tibial artery. Because the
measured value varies widely in case of arrhythmia, the
BP values should be averaged with more than three
times of measurement [2].
Home blood pressure measurement
Recommendations Class Level References
• Home BP measurement is recommended
to diagnose sustained HTN, white coat HTN
and masked HTN and to estimate prognosis.
I A [3]
• For accurate home BP measurements,
accurate measurement method should be
educated to all patients.
I C [4]
BP outside the office (out-of-office) can be measured
by home BP measurement and ABPM. Recently,
electronic sphygmomanometers using the vibration
method have been widely used for their convenience and
accuracy. Out-of-office BP measurement provides better
prognostic information than does office BP
Table 1 Blood pressure measurement
• Rest for 5 or more minutes in a quiet, appropriate environment
• Avoid smoking, alcohol or caffeine before measurement
• Measure 2 or more times at 1- to 2-min intervals at a single visit
• Use a cuff with a bladder at least 40% of the arm circumference wide;
80% of arm circumference long (a standard bladder for adults: 13 cm
wide; 22–24 cm long)
• Maintain the upper arm cuff at the heart level
• Inflate the cuff rapidly and deflate slowly at a speed of 2 mmHg
per heart beat
• Identify the blood pressure as the systolic blood pressure at the first
Korotkoff sound; the blood pressure as the diastolic blood pressure at
the fifth Korotkoff sound
• Consider the blood pressure as the diastolic blood pressure at the
fourth Korotkoff sound in pregnancy, arteriovenous shunt, and chronic
aortic insufficiency
• Measure blood pressure in both arms on the initial visit; subsequently
use the arm of higher pressure to measuring blood pressure
• Measure blood pressure in legs to exclude peripheral arterial disease,
when pulses in the lower extremities are weak
• Repeating the measurement three or more times to estimate the
average systolic and diastolic pressure in case of arrhythmia
• Measure blood pressure after 1- and 3-min standing in elderly persons
and persons with diabetes and suspected orthostatic hypotension
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measurement alone [3]. Home BP measurement is be-
coming increasingly important in not only for diagnosis
but also for management of HTN. However, since home
BP should be measured in a standardized way, patients
should be educated on accurate measurement methods
as shown in Table 2 (http://www.koreanhypertension.
org/sense/family).
Since the finger sphygmomanometer may be
inaccurate, the upper arm sphygmomanometer should
be used. The wrist sphygmomanometer should be allow
the positioning of the cuff at the height of the heart,
which might be useful in measuring BP in very obese
patients, especially in the upper arm. White coat HTN
refers to the untreated condition in which BP is elevated
in the office, but is normal when measured by ABPM,
home BP measurement, or both. Conversely, masked
HTN refers to untreated patients in whom BP is normal
in the office, but is elevated when measured by ABPM
or home BP measurement (Table 3).
Home BP measurement is recommended to diagnose
sustained HTN, white coat HTN and masked HTN and
to estimate prognosis. There is also evidence that home
HTN monitoring may have a beneficial effect on
medication adherence and BP control [5, 6].
Generally, home BP is lower than office BP. HTN is
regarded as home BP is defined as 135/85 mmHg or
more. “Morning HTN” is defined as BP measured in the
morning is higher than 135/85 mmHg and higher than
BP measured before sleep. When diagnosing HTN by
HBPM, it is recommended to measure BP for more than
5 days a week, 1 to 3 times in the morning and night.
After removing the BP value of the first day of the
evaluation, the values are averaged. In the morning, it is
recommended to measure BP within 1 h of waking up,
after voiding the bladder, and before taking
antihypertensive medication. In the evening, it is
recommended to measure BP before going to bed.
When HTN is first diagnosed, a seven-day average BP
value is recommended. Recommendations of home BP
measurement are as shown in Table 2 [7].
Ambulatory blood pressure measurement
Recommendations Class Level References
•Ambulatory blood pressure monitoring can
be used for a number of clinical indications,
such as identifying white coat and masked
HTN, quantifying the effects of treatment,
and estimating prognosis.
IIa A [8, 9]
Ambulatory BP measurement provides information on
the BP during the daytime, nighttime, and specific periods,
for example, early morning. Measurement of BP is
performed at 15–30min intervals over a 24-h period. Am-
bulatory BP measurement provides better prognostic infor-
mation than does BP measurement in the clinic. The mean
daytime ambulatory BP criterion for HTN is the same as
for home BP (i.e., 135/85mmHg or more) (Table 3). Am-
bulatory BP measurement is useful in clinical conditions
such as white coat HTN, masked HTN, resistant HTN, la-
bile HTN, HTN in pregnancy, and autonomic dysfunction
and also when accurate measurement of BP is required for
risk assessment or for the precise evaluation of BP lowering
efficacy [10]. A morning surge is considered to be a risk
factor for CVD, particularly stroke [11]. BP shows a diurnal
rhythm, being higher during waking hours and lower dur-
ing sleep. Normally, the average BP is 10–20% lower at
nighttime than during the day (dipper). A difference of less
than 10% (non-dipper) or an increase in the nighttime BP
relative to the daytime BP (riser) is associated with in-
creased risk of death, myocardial infarction, and stroke
[12]. A decrease of 20% or more (extreme dipper) may be
associated with increased risk for ischemic stroke and ath-
erosclerosis [13]. Risers may have autonomic dysfunction
and are at increased risk for hemorrhagic stroke [14].
When measuring ambulatory BP, it is important to instruct
the patient to engage in his or her ordinary daily activities
but to avoid strenuous exercise and also to hold the arm
still and in extension during cuff inflation. It is also neces-
sary to educate the patient on how to keep a diary and
how to turn off the monitoring device.
Table 2 Measurement of home blood pressure monitoring
• Use an upper arm cuff
• Time of measurement should be
1. Morning: within 1 h after waking up, after urination, before taking
antihypertensive drugs, before breakfast, after a 1–2 min rest in a
seated position
2. Night: before retiring, after a 1–2 min rest in a seated position
3. Other conditions if necessary
• Frequency of measurement: one to three times per occasion
• Period of measurement: as long as possible; 1 week or more for the
diagnosis of hypertension; over at least 5–7 days immediately
preceding the visit during follow-up of treatment











Home blood pressure ≥135 ≥85
Automated office blood pressure ≥135 ≥85
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Automated office blood pressure measurement
Recommendations Class Level References
•Automated office blood pressure can be
measured to exclude white coat HTN.
IIa B [15]
Autimate office blood pressure (AOBP) is measured by
setting the measurement time of the automatic
sphygmomanometer in advance, after a 5-min rest in room
alone without medical staff, and measuring the average value
of BP three times at 1-min intervals. The reference value for
HTN diagnosis is similar to home BP and daytime ambula-
tory BP, however the relationship between BP readings ob-
tained with conventional office BP measurement and
unattended office BP measurement remains unclear [16–18].
The AOBP measurement may reduce the white coat
effect and should be considered when it is difficult to
measure home BP or ambulatory BP, as it is useful for
repeated measurement; nevertheless, it is disadvantageous
for diagnosing masked HTN.
Central blood pressure measurement
Approximately 80% of the brachial arterial pressure can be
attributed to the central arterial pressure. In addition, the
central BP has been reported to be more closely correlated
with target organ damage or prognosis. Although it might
be useful for patients with significant differences between
the central arterial pressure and brachial artery pressure, it
is not usually recommended to replace conventional
brachial BP [19, 20].
Evaluation of the patient
Diagnosis and examination are aimed at: 1) differentiating
primary and secondary HTN; 2) evaluating the severity of
HTN; 3) identifying CV risk factors and lifestyle issues; and
4) searching for CVD, comorbidity, or subclinical organ
damage that could affect the choice of treatment.
Symptoms and signs
Patients with HTN most often have no specific symptoms
of BP elevation. HTN is usually found incidentally or else
it is detected in conjunction with symptoms of
hypertensive CVD or an underlying secondary cause of
HTN. Headache is often considered a symptom of HTN,
however, there is no significant correlation between BP
and headache except in cases of severe HTN. Headache
accompanied by HTN is commonly localized at the back
of the head, occurs early in the morning upon awakening,
and subsides spontaneously during the day. Some patients
with HTN exhibit general, non-specific symptoms such as
dizziness, palpitation, fatigue, and sexual dysfunction. The
symptoms of hypertensive CVD are hematuria, blurred
vision, dizziness due to transient ischemic attack, angina,
and shortness of breath due to heart failure. In some rare
cases, chest pain due to aortic dissection or aortic
aneurysm can occur. Patients with secondary HTN can
have specific symptoms and signs suggestive of the under-
lying causes. For example, patients with sleep apnea syn-
drome may experience early morning headache, excessive
daytime sleepiness, depression, reduced concentration,
and nocturnal shortness of breath. Patients with primary
aldosteronism may have polyuria, polydipsia, and episodes
of muscle weakness. Patients with Cushing’s syndrome
may have weight gain and emotional instability and those
with pheochromocytoma, episodic headache, palpitation,
sweating, and orthostatic hypotension.
Medical history
The medical history includes: 1) personal history of present
illness, past history, and family history; 2) symptoms and
signs suggestive of secondary causes of HTN; 3) symptoms
and signs of target organ damage; 4) CV risk factors; 5)
concomitant diseases; 6) lifestyle factors such as diet,
smoking, alcohol consumption, physical inactivity, exercise,
sleep, and personality/psychological status; 7) duration and
previous level of HTN, previous treatment and its results,
and adverse effects of antihypertensive therapy; 8) use of
nonsteroidal anti-inflammatory drugs, oral contraceptives,
herbs, and other drugs; and 9) socioeconomic status.
Physical examination
Physical examination of hypertensive patients includes 1)
measurement of BP in both arms as well as the pulse rate at
the first visit; 2) measurement of height and weight to
calculate the body mass index (BMI) as well as
measurement of waist circumference; 3) auscultation for
bruits over the carotid arteries, abdomen, and femoral
arteries; 4) palpation of the thyroid; 5) examination of the
heart and lungs; 6) examination of the abdomen for kidney
enlargement, masses, bladder distension, and abnormal
aortic pulsation; 7) examination of the lower extremities for
edema and palpation of the pulses; and 8) neurological
examination. Waist circumference is measured with a tape
measure at the level midway between the lowest rib and the
iliac crest with the patient in a standing position, at the end
of normal expiration, with the abdomen exposed and
without compression of the abdominal skin.
Laboratory examinations
Recommendations Class Level References
• It is recommended that the routine
laboratory tests should be evaluated at the
first visit and annually.
IIa C
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Laboratory examinations are performed to identify
additional CV risk factors, secondary causes of HTN,
subclinical organ damage, and concomitant diseases.
Routine laboratory tests should be performed before
antihypertensive treatment. Other recommended and
extended tests may be performed if necessary (Table 4).
In the 12-lead electrocardiogram (ECG), the findings
of left ventricular hypertrophy (LVH), left bundle branch
block, and myocardial infarction are regarded as high
risk for CVD. Proteinuria or hematuria suggests chronic
kidney disease (CKD), and glycosuria suggests diabetes
mellitus (DM). Blood hemoglobin and hematocrit levels
can determine anemia. An increase in the volume of red
blood cells is related to an increase in BP, but its correl-
ation coefficient is very low. If hypokalemia is observed
in the baseline evaluation, it suggests excessive state of
inorganic corticoids such as primary aldosteronism as a
cause of HTN. In addition, baseline potassium levels
should be evaluated because thiazide or loop diuretics
can lose serum potassium. Hypokalemia is associated
with increased lethargy, arrhythmias, and the incidence
of diabetes. Conversely, hyperkalemia can be indicated
by impaired renal function. An increase in serum cre-
atinine level or a decrease in the calculated glomerular
filtration rate (GFR) (< 60mL/min/1.73 m2) indicates a
decrease in kidney function. An increase in uric acid
level is observed in gout, impaired renal function, obes-
ity, or diuretic use. Estimation of fasting blood glucose
and lipid tests are necessary for confirming hypergly-
cemia and dyslipidemia, respectively. In addition, when
diuretics and beta-blockers are used over the long term,
the incidence of hyperglycemia and dyslipidemia
increases, which can be evaluated by routine tests. In-
creased cardiac/thoracic ratio on chest X-ray shows
cardiac hypertrophy, an increase pulmonary perfusion
and pulmonary edema suggests heart failure. Calcifi-
cation of the aortic arch shows arteriosclerosis. Basic
laboratory tests should be evaluated at the first visit
and annually.
Cardiovascular risk factors and subclinical organ damage
HTN is frequently accompanied by other CV risk
factors, therefore BP reduction alone is insufficient to
control the overall CV risk [21]. In patients with high
CV risk estimated or with target organ damage, lifestyle
modification for BP reduction is recommended even in
the prehypertensive range. However, there is little data
for CV risk stratification for Korean patients with HTN.
Table 5 shows the factors in addition to the BP level that
are used for evaluation of the risk for future CV events,
such as 1) risk factors: age, smoking, obesity,
dyslipidemia, increased fasting blood glucose, familial
history of premature CVD, and DM; 2) signs of
subclinical organ damage: (micro) albuminuria, LVH,
retinopathy, atherosclerosis, and increased arterial
stiffness; 3) clinical CVD: cerebrovascular disease, heart
disease, CKD, and peripheral vascular disease [22].
These predictors of the individual patient’s risk are very
useful for making clinical decisions, and studies are
therefore needed to develop a risk-stratification system
specific to the Korean population.
Risk stratification system of hypertension
The risk stratification of HTN in Korea was based on
the Korean Medical Insurance Corporation (KMIC)
study data, which were drawn from a population with
the following characteristics: 1) individuals registered in
the early 1990s; 2) relatively young age range of 35–59;
and 3) relatively high socio-economic status [23]. As a
result, this stratification may have limitations and may
underestimate the absolute CV risk of HTN of the gen-
eral population. Therefore, based on the KMIC data, this
guideline has defined the average risk as a 2-fold higher
risk than ‘the lowest risk group’, and categorizes the
overall risk into three groups: ‘the lowest risk group’, ‘the
moderate added risk group’ as higher risk than the aver-
age risk, and ‘the high added risk group’ as a 2-fold
higher risk than the moderate risk group [24, 25]. The
lowest CV risk was identified the patients in their 40s
Table 4 Laboratory examination
Routine tests
12-leads electrocardiogram (ECG)
Urinalysis – proteinuria, hematuria, glucosuria
Hemoglobin, hematocrit
K+, creatinine, estimated glomerular filtration rate (eGFR)a, uric acid,
Fasting glucose, lipids [total cholesterol, high-density lipoprotein
(HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol,
triglyceride]
Chest X-ray
Microalbuminuria: albumin/creatinine (in random urine sample)
Recommended tests




Ankle-brachial blood pressure index
Pulse wave velocity
Fundoscopy (mandatory in diabetes)
24-h urine protein excretion
Extended tests
Search for sub-clinical organ damage: brain, heart, kidney, vessels
Search for secondary causes of hypertension
aby CKD-EPI equation
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with HTN in the KMIC data with a 2–3% (about 2.5%)
10-year CV risk, corresponding to a 10-year CV event
rate for ‘the average risk’ patients of 5%. Accordingly,
the 10-year CV event rates for the lowest, the low added,
the moderate added, and the high added (including the
highest added risk group) risk groups were < 5%, 5–10%,
10–15%, and ≥ 15% (≥20% for the highest risk group),
respectively. These levels correspond to the rates of
< 5%, 5–15%, 15–20%, and ≥ 20% in the European
guideline [1].
In the risk table derived from the KMIC data, patients
with the grade 1 HTN who are in their 40s and have no
other CV risk factors have a risk of 4.3–5.3%; some of
them may exceed the average risk, whereas the women
in this group have a risk of 4.0–4.9%, which is below the
average risk [23]. Because the KMIC risk table
categorized age as 10-year units, it limits the precise
changes in CV risk with respect to age and sex. How-
ever, women with HTN over age 50 have a clearly higher
CV risk than the average. Therefore, ageing ≥45 years in
men and ≥ 55 years in women are considered CV risk
factors. If the patients aged over 50 years have a systolic
BP ≥130 mmHg, smoking and hypercholesterolemia,
their 10-year CV risk is estimated to be 9.8–11%, mean-
ing that even a patient with only prehypertension could
be stratified as at least moderate added risk if the indi-
vidual has 3 risk factors. Subjects in their 60s with pre-
hypertension and 3 risk factors clearly belong to the
high added-risk group.
Compared with the CV risk score derived from the
Korean Heart Study (KHS), the atherosclerotic CVD
(ASCVD) risk score (white) of the American Heart
Association/American College of Cardiology overestimates
CVD risk of the Korean population by 20–60% especially
for high risk patients. The CV risk score derived from the
KHS is well correlated with that of the KMIC data, and
better estimates the risk score in the elderly population
because the mean age of KHS is older than the KMIC [26].
As a result of age-based simulation, most individuals aged
65 years or older are classified as high risk individuals from
the pre-hypertensive stage, thus this guideline doubles the
age risk if the age is over 65 years old [27–29]. However, it
is limitation that there is no direct evidence from epidemi-
ology data derived from a national-representative popula-
tion. Therefore, better-designed prospective observational
studies are needed to provide a more representative or
clearer estimation of individual risk. The CV risk can be
stratified using the BP level, number of risk factors, evi-
dence of subclinical organ damage, and clinical CVDs, as
shown in Table 6.
Symptoms of and screening tools for secondary
hypertension
The prevalence of secondary HTN is approximately 5%
of all patients with HTN. Additional testing should be
performed in the following cases: 1) secondary HTN
suggested by age, medical history, physical examination,
basic laboratory examination, and the severity of HTN;
2) poor response to antihypertensive drugs; 3) BP
resistant to previously effective treatment for no
apparent reason; and 4) sudden onset of HTN. In some
cases, secondary HTN can be cured by surgery or drug
therapy. Renovascular HTN is suspected among patients
with HTN beginning at the age of ≤30 or ≥ 55 years,
worsening of previously well-controlled HTN, an ab-
dominal bruit, resistant HTN, an increase in the creatin-
ine level of > 30% over the baseline level following the
administration of an angiotensin converting enzyme
(ACE) inhibitor or angiotensin II receptor blocker
(ARB), and the presence of atherosclerotic disease in
other organs. Screening for renovascular HTN is per-
formed by using the captopril renal scan, Doppler ultra-
sound (US), computed tomography (CT), or magnetic
Table 5 Cardiovascular risk factors and subclinical organ damage
Risk factors for cardiovascular disease
• Age (men ≥45 years old, female ≥55 years old)a
• Smoking
• Obesity (body mass index ≥25 kg/m2) or abdominal obesity (waist
circumference men > 90 cm, women > 85 cm)
• Dyslipidemia [total cholesterol ≥220mg/dL, low-density lipoprotein
(LDL)-cholesterol ≥150 mg/dL, high-density lipoprotein (HDL)-
cholesterol < 40 mg/dL, triglycerides ≥200mg/dL]
• Pre-diabetes [impaired fasting glucose (100≤ fasting blood glucose
< 126mg/dL) or impaired glucose tolerance]
• Family history of premature cardiovascular disease (men < 55 years,
women < 65 years)
• Diabetes mellitus [fasting blood glucose ≥126mg/dL, postprandial 2-h
glucose (oral glucose tolerance test) ≥200mg/dL, or hemoglobin
A1C ≥6.5%]
Subclinical organ damage
• Brain – periventricular white matter hyperintensity (PWMH),
microbleeds, asymptomatic cerebral infarction
• Heart – left ventricular hypertrophy, angina pectoris, myocardial
infarction, heart failure,
• Kidney – albuminuria, decreased estimated glomerular filtration rate
(eGFR) (eGFR < 60 ml/min/1.73m2, chronic kidney disease)
• Blood vessels – atherosclerotic plaque, carotid-femoral pulse wave
velocity > 10 m/sec, brachial-ankle pulse wave velocity > 18 m/sec,
coronary calcification.
• Retina - stage 3 or 4 hypertensive retinopathy
Clinical cardiovascular or renal diseases
• Brain – Stroke, transient ischemic attack, vascular dementia
• Heart – angina, myocardial infarction, heart failure, atrial fibrillation
• Kidney – chronic kidney disease stage 3, 4, or 5.
• Blood vessels – aortic aneurysm, aortic dissection, peripheral
vascular diseases
aAge ≥ 65 regarded as 2 risk factors
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resonance angiography. Hypokalemia with no apparent
cause or an incidentally diagnosed adrenal mass are indi-
cations for evaluation for hyperaldosteronism. Paroxysmal
and/or refractory HTN accompanied by hyperadrenergic
symptoms suggests the possibility of pheochromocytoma,
which is an indication for measurement of the catechol-
amine level in the plasma and/or 24-h urine, CT, magnetic
resonance imaging, or radioisotope imaging (I-131
metaiodobenzylguanidine) (Table 7). In recent years, sleep
apnea syndrome has been suggested as the leading cause
of secondary HTN. Although there is still no evidence of
the benefits for or the confirmation of screening tests, the
prevalence of sleep apnea is high among obese patients or
those with resistant HTN and can be screened by self-
questionnaire or diagnosed by sleep polysomnography.
Chapter II. Treatment of hypertension
Treatment of hypertension
The purpose of HTN treatment is to prevent CVD
caused by increased BP and to reduce mortality by
controlling high BP. In patients who already have
established CVD, treatment aims to control BP to
prevent progression or recurrence of disease in order to
decrease mortality and improve quality of life. HTN
treatment provides greater benefit in patients who are at
higher risk for CVD. Most clinical studies of HTN have
found that lowering SBP by approximately 10–20 mmHg
or DBP by approximately 5–10mmHg can reduce the
occurrence of stroke by 30–40% and that of ischemic
heart disease by 15–20% [30]. Because most clinical
studies were performed over a relatively short period,







Risk factor 0 Lowest risk group Low added risk group Moderate to high added
risk group




High added risk group
Risk factor≥ 3, DM, sub-clinical organ damage Moderate to high added
risk group
High added risk group High added risk group
DMa, cardiovascular disease, chronic kidney disease High added risk group High added risk group High added risk group
aComplicated by sub-clinical organ damage or cardiovascular diseases
Table 7 Clinical clues and diagnoses of secondary hypertension
Diseases Clinical clues Diagnoses
History Physical diagnosis Chemistry Screening test Additional test
Parenchymal
renal diseases
Urinary tract infection or
obstruction, analgesic abuse,
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the benefits of HTN treatment over a period of 5 years
or more seem to be much more pronounced than the
treatment efficacy observed in clinical studies. The
benefits of HTN treatment are not affected by sex or age
and are similar for the treatment of systolic HTN in the
elderly. HTN treatment was found to be the most cost-
effective intervention for prevention of CVD.
Strategy for hypertension treatment
If a patient is already known to have high BP, the
diagnosis of HTN must be confirmed prior to treatment
by measuring the out-of-clinic BP, such as at home BP
or using 24-h BP monitoring. Measurement of out-of-
clinic BP helps not only to obtain a more accurate diag-
nosis but also to determine the appropriate treatment
for the patient and to increase treatment adherence. If
HTN is diagnosed, the risk factors for CVD, associated
diseases, and existence of hypertensive complications
should be investigated (Fig. 1).
Patients with white coat HTN, defined as high BP in
but not out of the clinic, must be followed up
periodically at 3–6-month intervals because their risk of
CVD increases over time. HTN treatment must include
non-drug therapy (such as lifestyle modifications) concomi-
tant with drug therapy. The initiation of drug therapy needs
to be considered and determined on the basis of not only
the BP level but also the presence of risk factors for CVD
and evidence of damage to target organs. Drug therapy
may be used in patients with a BP of 140/90mmHg or
higher regardless of the existence of other risk factors or as-
sociated diseases. The quality of life of patients with HTN
can be affected by physical and psychological problems
caused by HTN, the main and side effects of the drug, and
the relationship between the patient and physician. Ad-
equate communication and provision of information can
decrease the dosage and frequency of medication used,
which increases patient adherence, improves the BP control
rate, and promotes continuous treatment.
Initiation of hypertension treatment
Prehypertension
Recommendations Class Level References
• Generally, drug therapy is not
recommended in prehypertension.
III A [31, 32]
• In populations with elevated BP and in
the prehypertensive range, instructions for
lifestyle modifications should be provided
for the prevention of HTN development and
CVD.
I B [33–36]
• In the high risk HTN patients* with
systolic BP over 130 mmHg by AOBP
measurement, it is recommended to
provide drug therapy along with lifestyle
modifications.
IIa B [37]
• In the population within the
prehypertensive range, ambulatory BP
monitoring or home BP measurement is
recommended to exclude masked HTN.
IIa B [38]
Fig 1 Treatment strategies for hypertension, BP; blood pressure, CV; cardiovascular, HTN; hypertension, *; recommended test
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*Patients ≥50 years old with CVD, PAD, aortic disease,
heart failure or LVH
CV mortality caused by HTN increases 2-fold for each
20-mmHg increase in SBP or 10-mmHg increase in DBP
over the baseline level of 115/75mmHg. Therefore, in
patients with BP over 120/80 mmHg, non-drug therapy
is recommended to prevent the occurrence of HTN and
CV events [31, 32].
Initiation of drug therapy in patients with
prehypertension can delay the progression to HTN
[39, 40], but there is little evidence for the
effectiveness of early intervention in most clinical
studies [32]. The Heart Outcome Prevention
Evaluation-3 (HOPE-3) trial in the intermediate-risk
group also had no effect on drug therapy, but an add-
itional analysis suggested the possibility of drug treat-
ment in patients with BP over 140 mmHg [31].
Initiation of drug therapy in the prehypertensive
range showed no consistent benefit in patients with
prediabetes [41, 42], DM [43], stroke [44], or coron-
ary artery disease (CAD) [45]; therefore, the cost-
benefit aspect should be considered in the decision to
use drug therapy (Table 8).
Systolic Blood Pressure Intervention Trial (SPRINT)
subgroups whose systolic BP are more than 130
mmHg measured by AOBP, who have a history of
CAD, peripheral vascular disease, aortic disease, heart
failure, or LVH, may consider drug therapy on top of
intensive lifestyle modifications [37]. The reason for
restricting drug therapy for SPRINT subgroups is that
the definition of high risk patients assessed by the
ASCVD risk score is not suitable for Korean patients
and cannot be generalized for the elderly and patients
with CKD.
Grade 1 hypertension
Recommendations Class Level References
• In patients with grade 1 HTN at low risk,
BP-lowering drug treatment is recom-
mended if the patient remains hypertensive
after a period of lifestyle intervention.
I B [31, 46, 47]
• In patients with grade 1 HTN and at
moderate-to-high risk, prompt initiation of
drug treatment is recommended along with
lifestyle interventions.
I A [31, 48, 49]
Patients with grade 1 HTN without any other risk factors
are in the low risk group and would not be expected to
obtain a greater benefit from treatment [50]. However, their
overall risk will increase over time, and the window in
which treatment could reverse progression might be
missed. In addition, the risk of CVD is low, thus lifestyle
modifications can be actively attempted before starting
drug treatment. However, it is recommended to begin drug
treatment as soon as possible when lifestyle modification is
considered ineffective, when CV risk factors are revealed
during lifestyle modification, and when patients are unable
to regularly visit and receive guidance of lifestyle
modification. In general, it is desirable to consider lifestyle
modification as an adjunct, not as an alternative to
medication. Current antihypertensive drugs are generally
inexpensive and safe, and drug therapy has been found to
be cost-effective given that patients generally fail to accom-
plish lifestyle changes. Drug therapy is recommended only
after measurement of the out-of-clinic BP in order to ex-
clude the possibility of white coat HTN [51, 52]. The effect
of drug therapy on white coat HTN has not yet been dem-
onstrated; however, as white coat HTN poses increased
Table 8 Drug treatment for hypertension according to the risk. BP, blood pressure; DM, diabetes mellitus
Lee et al. Clinical Hypertension           (2019) 25:20 Page 9 of 24
metabolic risk and risk for CV events over the long term,
lifestyle modification is recommended at first, and patients
should be observed periodically for development of persist-
ent HTN [31, 53]. Drug therapy should be instituted imme-
diately in patients with high risk grade 1 HTN [46, 48, 49].
Grade 2 hypertension
Recommendations Class Level References
• In patients with grade 2 HTN, prompt
initiation of drug treatment is recommended
along with lifestyle interventions.
I A [46, 48, 49]
According to most randomized clinical trials and meta-
analyses, immediate drug therapy is warranted in patients
with a BP of ≥160/100mmHg due to the significant benefit
of drug treatment [32, 48, 49].
Hypertension in the elderly
Recommendations Class Level References
• BP-lowering drug treatment and lifestyle
modifications are recommended for fit older
patients (> 65 years but not > 80 years)
when SBP is over 140 mmHg.
IIa B [54]
• BP-lowering drug treatment and lifestyle
modifications are recommended for frail
older patients or older patients (> 80 years)
when SBP is over 160 mmHg.
I A [54, 55]
The effect of drug therapy against HTN is clear
irrespective of age. BP-lowering drug treatment and life-
style modifications are recommended for frail older pa-
tients or older patients (> 80 years) when SBP is over
160 mmHg. Drug therapy can be considered if the SBP
is 140–159 mmHg and the patient tolerates hypertensive
medications well.
Target blood pressure in the treatment of hypertension
Recommendations Class Level References
• For hypertensive patients at low to
moderate risk, target BP of 140/90mmHg is
recommended.
I A [31, 53]
• For patients with CVD (over age 50 with
CAD, PAD, aortic disease), congestive heart
failure (CHF), or LVH, a target BP of 130/80
mmHg can be considered (SPRINT eligible
population).
IIa B [37]
• For high risk patients with 10-year CVD
risk of > 15%, a target BP of 130/80mmHg
can be considered*.
IIa B [56, 57]
*Elderly (≥65 years old), CKD patients will be
recommended separately.
Except under specific circumstances as shown in
Table 9, the target BP is generally a SBP of less than 140
mmHg and DBP of less than 90mmHg [32, 58, 59]. For
patients with CVD (over age 50 with CAD, PAD, aortic
disease), CHF, or LVH, a target BP of 130/80 mmHg can
be considered (SPRINT eligible population) [37, 56]. In
contrast, for hypertensive patients at low-to-moderate
risk, a target BP of 140/90 mmHg is recommended [31]
(Fig. 2).
Hypertension in the elderly
Recommendations Class Level References
• For elderly hypertensive patients, a target
SBP < 140mmHg can be considered.
IIa B [54, 60, 61]
Although it has previously been reported that there
was no difference in prognosis between BP targets of
140 mmHg and 150 mmHg [62], the SPRINT trial
showed clear evidence of BP lowering effects in elderly
patients with HTN [37]. Therefore, the target SBP is
below 140mmHg with a DBP that is not excessively low,
i.e., less than approximately 60 mmHg [62, 63] (Fig. 2).
Hypertension in patients with diabetes mellitus
Recommendations Class Level References
• It is recommended that SBP be lowered
to below 140mmHg in hypertensive
patients with diabetes.
I A [59, 64–67]
• It is recommended that DBP be lowered
to below 85mmHg in hypertensive patients
with diabetes.
I B [68, 69]
• In diabetic patients with CVD, a target BP
< 130/80 mmHg can be considered.
IIa C [70]
Table 9 Summary of office blood pressure target goal. BP,
blood pressure; DM, diabetes mellitus
Conditions Systolic BP (mmHg) Diastolic BP (mmHg)
Uncomplicated, general < 140 < 90
Elderly < 140 < 90
DM
Uncomplicated < 140 < 85
Complicateda < 130 < 80
High riskb ≤ 130 ≤ 80
Cardiovascular disease ≤ 130 ≤ 80
Cerebrovascular disease < 140 < 90
Chronic kidney disease
No albuminuria < 140 < 90
Albuminuriac < 130 < 80
aComplicated by sub-clinical organ damage or cardiovascular diseases. bHigh
risk, elderly patients should be followed elderly patients criteria.
cincluding microalbuminuria
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Reduction of BP in patients with HTN and DM is very
important for reducing CV complications [71]. Few studies
have shown reduction of SBP to below 130mmHg. Even
reduction of SBP to less than 120mmHg did not
demonstrate any additional preventive effect on CVD but
rather showed a deleterious effect on renal function;
therefore, the recommended target BP is an SBP below 140
mmHg [59, 64–67] and a DBP below 85mmHg [68, 69].
The Action to Control Cardiovascular Risk in Diabetes
(ACCORD) study sub-analysis of a SPRINT-eligible popu-
lation showed an overall reduction in CV events with inten-
sive BP lowering to < 130/80mmHg, therefore in DM
patients with CVD, a target BP < 130/80mmHg can be
considered [70] (Fig. 2).
Hypertension in patients with stroke HTN is a most
important causative risk factor for stroke. HTN treatment
can reduce the recurrence of stroke and CV events [72–
74], but there are no distinct benefits from reducing SBP to
below 130mmHg [75]. In particular, a recent clinical study
in patients with cerebral infarction showed no additional
benefit from controlling SBP below 140mmHg [76].
Considering the clinical studies to date, a target SBP below
140mmHg is recommended in patients with stroke (Fig. 2).
Hypertension in patients with coronary artery disease
Reduction of SBP to below 130mmHg shows no consistent
prevention of CVD in patients with HTN and CAD [77–
79]. However, based on multiple meta-analyses and
SPRINT study result, a target SBP of around 130mmHg
can be considered [56, 57, 77] (Fig. 2).
Hypertension in patients with chronic kidney disease
Recommendations Class Level References
• For CKD patients with HTN, target BP of
140/90mmHg is recommended.
I A [64, 80, 81]
Chapter II. Treatment of hypertension (Continued)
• For CKD patients with HTN and
albuminuria, a target BP <130/80mmHg
can be considered.
IIa B [22, 82]
The main aim of controlling BP in patients with CKD
is to prevent deterioration of renal function and reduce
the occurrence of CVD. Further control of SBP to below
140mmHg has shown no additional benefit in patients
with HTN and CKD without DM [83–85]. However, the
data on the goal of treatment in patients with HTN and
CKD with DM is even scantier [82, 86]. Meta-analyses
have not proven that a target BP of less than 140 mmHg
is any more effective at preventing cardiac and renal
events [64, 80, 81]. Therefore, based on recent clinical
data, a target SBP of less than 140mmHg is recommended
regardless of the presence of DM. However, a target SBP
below 130mmHg can be recommended in patients with
HTN with prominent albuminuria [22] (Fig. 2). Even
though the SPRINT study enrolled CKD patients, the
results cannot be generalized to recommend a target SBP
< 130mmHg overall for CKD patients [87].
Lower limit blood pressure of hypertension treatment
Recommendations Class Level References
• If SBP drops to 110mmHg and DBP falls
to below 70mmHg, the risk of mortality
and the risk of developing CAD may
increase. Lowering DBP to below 70mmHg
should be carefully considered in the
elderly, in DM, and in multiple CAD without
revascularization, and HTN patients with
LVH.
IIb C [88–91]
As BP increases, the CV risk also increases, whereas as
BP decreases, the risk of the occurrence of a CV event
Fig. 2 The algorithm and level of evidence of target BP in various clinical conditions
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decreases to some extent. There is insufficient clinical
data to prove the J-curve hypothesis (the hypothesis that
excessive lowering of SBP and DBP will increase rather
than decrease CV events and mortality), however a post-
hoc analysis of clinical studies suggests the possibility of
such a J-curve effect and a pathophysiological detriment
of excessively low BP [92]. Therefore, it is not recom-
mended to target BP too low, but additional studies are
needed to determine how low a BP is desirable. That is,
1) elderly people who are likely to be associated with
CAD; 2) patients with multiple CAD who are not under-
going revascularization; 3) DM patients who are likely to
be associated with multiple CAD; 4) In HTN patients
with LVH, it can be considered not to lower DBP below
70mmHg [88–91].
Target blood pressure according to blood pressure
measurement methods According to the measurement
method, the BP outside the clinic is lower than the
office BP by about 5 mmHg for both SBP and DBP on
average. The target BP is 140/90 mmHg measured by
office BP may correspond to a mean home BP, the day-
time BP or 24-h ambulatory BP monitoring of 135/85
mmHg, 135/85 mmHg, and 130/80 mmHg, respectively.
However, since the difference in BP measured by the dif-
ferent BP measurement method is largely uneven de-
pending on the level of the BP and the individual
characteristics, and is not constant at the time of meas-
urement, it is necessary to consider the individual differ-
ences when converting the target BP [93]. In particular,
target BP according to an AOBP measurement may
overlook the masking effects.
Non-pharmacologic therapy and lifestyle modifications
Recommendations Class Level References
• Lifestyle modification is recommended in
the population with elevated BP and
prehypertension and all hypertensive
patients.
I A [94–97]
Non-pharmacologic therapy or lifestyle modifications,
such as adoption of a healthy diet, exercise, smoking
cessation, and moderation of alcohol intake, has shown
great impact to lower BP and is strongly recommended in
all patients with HTN and also in populations with elevated
BP and within the prehypertensive range (Table 10).
Healthy lifestyle habits have almost an equipotent BP-
lowering effect as approximately one dose of antihyperten-
sive drug [98]. Furthermore, in patients with HTN who are
using medication, adding lifestyle modification can reduce
the dose and frequency of medication used, maximize the
effects of the drug, and reduce side effects. Lifestyle
improvement also has other beneficial effects on CV risk in
addition to the lowering of BP. However, clinicians should
remain aware that it is difficult to maintain lifestyle modifi-
cations long-term or to achieve a target BP for the HTN in
grade 2 or higher even with the best attempts. Therefore,
the clinician should provide encouragement to continue
lifestyle modifications while also educating the patient in
their limitations. In addition, because adopting several types
of lifestyle modification rather than one alone maximizes
the effects, a simultaneous approach is recommended to
meet the goal of minimizing CVD.
Restriction of salt intake
Recommendations Class Level References
• Salt restriction to < 6 g per day is
recommended.
I A [94–96, 99–
101]
It is estimated that Koreans consume 10 g of salt daily
(sodium 3.9 g), which is a higher amount than Western
recommendations (salt 5 g). The main source of salt in
Korea is spices, vegetables, and grains [102–104].
Salt intake can increase the risk for CV events because
of the association of central hemodynamics rather than on
peripheral BP [105]. Halving the daily salt intake of 10 g
will decrease SBP by 4–6mmHg [106, 107]. However,
there have been variable and confusing reports about the
relationship between salt restriction and CV events [99–
101, 108]. Despite the absence of randomized large-scale
trials, some reports of a J-curve phenomenon for salt in-
take and CV events, and lack of Korean data, there is no
clear evidence that salt restriction is harmful, especially
among Koreans with high salt intake. Therefore, we must
recommend decreasing salt intake in accordance with
other guidelines [109].
The daily recommended amount of salt is less than 6 g
[sodium (g) × 2.5]. Salt reduction has many benefits,








-5.1/-2.7 Less than 6 g of salt per day
Body weight
reduction
-1.1/-0.9 Each reduction of 1 kg
Moderation
in drink
-3.9/-2.4 Less than two glasses per
day
Exercise -4.9/-3.7 30–50 min per day for more
than 5 days in a week
Diet control -11.4/-5.5 Vegetables-based healthy
diet habit*
*Diet rich in vegetables, fruits, and fish and low in fat and calorie
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including lowering of BP and reducing the need for
diuretics, which cause detrimental urinary loss of potassium
and calcium. The avoidance of urinary calcium loss prevents
the development of osteoporosis and renal calculi.
Sensitivity to salt tends to be higher in patients who are
elderly, obese, or have diabetes or family members with
HTN. Greater salt sensitivity means a greater reduction in
BP in response to salt restriction. Because of the high
correlation with salt intake and energy intake, reducing
caloric intake can reduce salt intake. Dietary habits must
be modified. Some recommendations are not to put
additional salt on the table during the meal and to avoid
high-salt processed foodstuffs. Some frequently eaten
foods, such as kimchi, stew, soup, salted fermented sea-
food, instant ramen, and dry bar snacks containing meat
and fish, are very salty. When cooking, natural ingredients
should be used instead of synthetic flavoring agents. The
patient should reduce absolute salt intake but also try to
consume more low-salt foods.
Eating potassium-rich foods can help prevent HTN,
and can lower BP in hypertensive patients. Potassium
can inhibit BP rise with salt intake by excreting sodium
outside the body. The higher the potassium intake, the
more potent the BP-lowering effect of potassium can be
achieved. However, attention should be paid to potas-
sium intake in patients with impaired renal function.
Weight reduction
Recommendations Class Level References
• Body weight control to reduce BMI < 25
kg/m2 is recommended for BP reduction.
I A [97, 110]
HTN is closely associated with obesity, and weight
reduction decreases BP. Central obesity in particular is
closely associated with HTN, dyslipidemia, diabetes, and
CV death. In a patient heavier than 110% of the ideal body
weight, a weight reduction of only 5 kg can decrease BP.
The beneficial effects of weight reduction are higher in
patients with diabetes, dyslipidemia, and LVH. The
combination of weight reduction with exercise, moderation
of alcohol consumption, and reduction of salt intake has
synergistic effects on BP. The recommended initial goal of
weight reduction is 4–5 kg, with an additional 5 kg
reduction after the initial goal has been achieved.
The ideal BMI [weight (kg)/height (m2)] varies among
reports and according to nationality. A collaborative
analysis reported that BMI either above or below the
apparent optimum of approximately 22.5–25 kg/m2 is
itself a strong predictor of overall mortality [110].
Another meta-analysis found that both overweight and
grade 1 obesity were associated with significantly lower
all-cause mortality [110]. A report on data from 1.2 mil-
lion Koreans revealed that the risk of death from any
cause was lowest among patients with a BMI of 23.0 to
24.9 kg/m2 and recommended a BMI of less than 25 kg/
m2. Unfortunately, there are no Korean-specific data on
appropriate waist circumference. A waist circumference
of less than 90 cm for men and 85 cm for women is rec-
ommended for Asian individuals.
The recommendations for weight reduction are to eat
breakfast every morning, eat slowly, and avoid a high-
carbohydrate diet, alcohol, snacks such as bread and
cookies, and sweetened beverages. A high-fiber diet is rec-
ommended and a high-fat diet including food fried with
oil is prohibited. Patients should try to eat as many fruits
and vegetables as possible and to avoid meals containing
large amounts of cholesterol and saturated fatty acids.
Moderation of alcohol consumption
Recommendations Class Level References
• It is recommended to moderate alcohol
consumption to less than 2 drinks per day.
I A [111]
BP tends to increase in patients who drink excessive
amounts of alcohol and such patients are also resistant
to antihypertensive drugs. An appropriate moderate
daily amount of alcohol is less than 20–30 g for men or
10–20 g for women. A man or woman with lower-than-
average body weight is more sensitive to alcohol and is
therefore permitted half of the recommended amount.
Heavy drinkers should be warned that they are high risk
for stroke. One bottle of beer (720 mL), 1 glass of wine
(200–300 mL), 1 glass of sake (200 mL), 2 shots of
whisky (60 mL), or 2–3 glasses of soju corresponds to
30 g of alcohol.
Exercise
Recommendations Class Level References
• Regular aerobic exercise (e.g. at least 30
min of moderate dynamic exercise 5–7 days
per week) is recommended.
I A [22, 112]
• It is recommended that isometric
exercise or isometric exercise, such as lifting
a heavy weight, can be performed
concurrently with aerobic exercise, but
should be avoided as BP may temporarily
rise when BP is not controlled.
I A [22, 112]
The benefits of regular exercise are lowering of BP,
improvement of cardiopulmonary function, reduction of
body weight, improvement of the lipid profile (including
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elevation of HDL-cholesterol), and reduction of emo-
tional stress. Aerobic exercises such as brisk walking,
jogging, bicycling, swimming, jumping rope, playing ten-
nis, and aerobic dancing are recommended for patients
with HTN [113]. The appropriate intensity of exercise is
60–80% of the maximal heart rate (220 minus age in
years). Such exercise should be performed 5–7 times per
week. Aerobic exercise should begin at low intensity for
10–20min and then increase to appropriate intensity for
another 30–60 min. It is best to exercise for 90–150 min
or more per week. Warm-up and finish exercises before
and after exercise session for five minutes is necessary.
In addition, isotonic muscle strength and isometric exer-
cise using muscular dumbbells two or three times a
week is recommended not only to reduce BP but also to
improve metabolic factors and strengthen muscles [114].
Isometric exercises using a hand dynamometer is used
to estimate the maximal handgrip power and then is
held for 2 min at a strength of 30–40% of the maximum
measured weight, followed by rest for 1 min for 4 times,
three days a week. It is recommended that isometric ex-
ercise or isometric exercise, such as lifting a heavy
weight, can be performed concurrently with aerobic ex-
ercise but should be avoided as BP may temporarily rise
when BP is not controlled. Most patients with uncompli-
cated HTN can begin regular exercise without an initial
evaluation and increase the duration and intensity to ap-
propriate levels as possible. However, patients with
known CVD or other risk factors are recommended to
start the exercise only after complete evaluation by an
exercise consultant and to follow a program.
Smoking cessation
Recommendations Class Level References
• Smoking cessation, supportive care, and
referral to smoking cessation programs are
recommended.
I A [115–117]
During smoking, the BP increases temporarily in
response to nicotine. Among patients with white coat
HTN, smokers maintain a higher daytime ambulatory SBP
than do non-smokers with a similar office BP [118]. Be-
cause smoking, like HTN, is a powerful risk factor for CVD
[115], CV events are inevitable in patients who continue
smoking regardless of BP control. Second-hand smoking is
also harmful. Smoking cessation should be advised at every
opportunity. Low-nicotine-containing replacement mate-
rials do not increase BP and can be recommended in com-
bination with behavior therapy. During smoking cessation,
regular exercise and diet therapy should be emphasized in
order to prevent weight gain.
Healthy diet
Recommendations Class Level References
• Increased consumption of vegetables,
fresh fruits, fish, nuts, and unsaturated fatty
acids; low consumption of red meat; and
consumption of low-fat dairy products
I A [82, 119,
120]
BP is lower in vegetarians than in people who mainly
eat meat, and maintaining a vegetarian diet can reduce
BP. The BP-lowering effect results not from decreasing
the intake of animal protein but from increasing the intake
of vegetables and fruits in combination with decreasing
the intake of saturated fatty acids. In a study in elderly
people, BP decreased by 3/1mmHg when intake of vege-
tables and fruits was increased alone but by 6/3mmHg
when it was combined with a decrease in fat intake [121–
123]. It is important for HTN patients to change the over-
all dietary pattern rather than diet that emphasizes specific
nutrients [119]. For example, Dietary Approaches to Stop
Hypertension (DASH), which includes consumption of
more fruits, vegetables, and fish and consumes less fat,
can lower BP by 11/6mmHg. Because it contains multiple
food groups, the DASH diet is likely to have additional
beneficial effects [121, 123, 124]. Regular intake of fish re-
duces BP in obese HTN patients and improves lipid me-
tabolism. In Korea, diets consisting of tofu, soybean, fruit,
vegetables, and fish were associated with a low prevalence
of HTN with a high dietary intake [125]. Therefore, a
healthy balanced diet such as DASH or a Mediterranean
diet for HTN patients is recommended not only to lower
BP but also to prevent CVD [119, 120].
Others
Caffeine from various foods rapidly increases BP, but the
effect does not progress to HTN because tolerance to
caffeine develops. Emotional stress increases both BP
and the risk for CVD, making the control of emotional
stress important for the management and patient
adherence of HTN. Further studies are required to
examine the long-term effects of stress control on HTN
and CVD. The effectiveness of various methods of stress
management, such as relaxation and biofeedback, for the
management of HTN remains uncertain. There is still
no clear evidence for the effects of micronutrients, cal-
cium, magnesium, and supplementary fiber on BP.
Pharmacological therapy for hypertension
Recommendations Class Level References
• Prompt initiation of BP-lowering drug
treatment is recommended in patients with
I A [126–128]
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Chapter II. Treatment of hypertension (Continued)
high risk or grade 2 HTN, simultaneous with
the initiation of lifestyle for achieving target
goal BP.
The occurrence of CV events in patients with HTN
can be decreased by reducing the BP. Currently available
antihypertensive drugs are more effective than placebo
for prevention of CVD. This preventive effect is
relatively larger for stroke than for CAD. The extent to
which CV events are reduced depends on the degree of
BP reduction. All major classes of antihypertensive
drugs, including beta-blockers and diuretics, are suitable
for first-line treatment. However, the individual drug
should be prescribed with consideration of the patient’s
individual situation, including age, comorbidities, and
possible adverse effects. Simplifying the medication
schedule, careful monitoring of the adverse effects, and
checking the BP at home are useful for improving pa-
tient adherence and making the patient an active partici-
pant in the treatment.
Strategies for prescription of antihypertensive drugs
Principles of drug selection
Recommendations Class Level References
• In patients with BP higher than 160/100
mmHg or more than 20/10 mmHg above
the target BP, two drugs can be prescribed
in combination to maximize the
antihypertensive effect and to achieve rapid
BP control.
IIa C [129]
For reducing long-term CV morbidity and mortality, it
is essential to control most of the modifiable risk factors
and to reduce the BP to less than 140/90 mmHg [22].
Drug therapy is initiated at a low dose to avoid adverse
effects. The preferred drugs are long-acting and can be
taken only once a day [130]. Drugs with a high trough/
peak ratio (T/P ratio > 0.5) are helpful for improving ad-
herence and to maintain a stable BP with minimal vari-
ability [131]. When it is difficult to control BP with
once-daily dosing, a twice-daily schedule is an alternative
option. ACE inhibitors, ARBs, calcium channel blockers,
beta-blockers, and diuretics are all agents suitable for
initiation of antihypertensive treatment. The indica-
tions, contraindications, comorbidities, and presence
of asymptomatic organ damage should all be consid-
ered in the choice of drug. Beta-blockers in the eld-
erly are controversial for treatment benefits and
should only be used if there is a specific indication.
Concomitant use of beta-blockers and diuretics
increases the risk of developing diabetes, so care
should be taken in patients at high risk of developing
DM [22]. In patients with BP higher than 160/100
mmHg or more than 20/10 mmHg above the target
BP, two drugs can be prescribed in combination to
maximize the antihypertensive effect and achieve
rapid BP control [22]. Single pill combination drugs
have multiple benefits, including maximizing reduc-
tion of BP, minimizing adverse effects, increasing
adherence, and preventing CVD and target organ
damage [132].
Selection of drugs It is reasonable to choose drugs
according to the patient’s comorbidities and clinical
characteristics rather than his or her BP level. There are
five available classes of first-line drugs with proven BP-
lowering effects, safety, and acceptable adverse effects
according to multiple studies. They are: 1) ACE inhibi-
tors or ARBs; 2) beta-blockers; 3) calcium channel
blockers; and 4) diuretics such as hydrochlorothiazide,
chlorthalidone, or indapamide. All reduce BP to a simi-
lar extent when the dose has been adjusted. However,
there might be individual differences in BP lowering, ad-
verse effects, and long-term CV events, making it very
important to choose the appropriate drugs according to
the patient’s combined risk factors and comorbidities
(Table 11). No antihypertensive drug is inherently super-
ior, and the drugs most appropriate for the individual
patient should be preferred (Table 12).
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Classes of antihypertensive drugs
Diuretics
Recommendations Class Level References
• Thiazide or thiazide-like diuretics can be
used as first-line drugs with a preference for
chlorthalidone or indapamide.
IIa B [133, 134]
• Loop diuretics can be considered in
patients with CHF, advanced CKD of stage
IV or stage V.
IIa B [135]
• In patients with resistant HTN,
aldosterone antagonists such as
spironolactone can be considered in the
absence of hyperkalemia.
IIa B [136, 137]
Diuretics decrease BP initially by reducing
reabsorption of sodium in the renal distal convoluted
tubules and later by decreasing peripheral vascular
resistance. High-dose thiazide-derivative diuretics can
induce hypokalemia, glucose intolerance, hyperuricemia,
arrhythmia, and adverse lipid metabolism, but low doses
rarely have these effects. Combination of diuretics with
beta-blockers is not recommended in patients with
obesity or at high risk of diabetes because of adverse
effects such as new-onset diabetes and adverse lipid
metabolism. Thiazide-like diuretics such as chlorthali-
done and indapamide have been found to be more ef-
fective than hydrochlorothiazide [133, 134, 138], but
should be aware of hyponatremia or hypokalemia.
Loop diuretics such as furosemide and torsemide are
administered in the presence of CHF or when the
GFR drops below 30 mL/min/1.73 m2 [135]. Spirono-
lactone has proven effective in patients with heart
failure and may be considered at low doses (25–50mg)
for treatment of resistant HTN.
Beta-blockers Selective beta-1 blockers are recom-
mended for patients with HTN in combination with
angina pectoris, myocardial infarction, or tachycardia.
Beta-blockers are also effective in younger patients who
have higher heart rates [22]. However, they should be
used with caution in patients with asthma, chronic ob-
structive pulmonary disease, second- or third-degree
atrioventricular block, or peripheral vascular disease
[22]. Beta-blockers can have adverse effects on blood
glucose and lipid metabolism and should therefore be
used cautiously in elderly patients or patients with ele-
vated blood sugar, diabetes, or metabolic syndrome
[139]. They should also be used carefully in patients with
variant angina because they can worsen symptoms [140].
Because atenolol is inferior for stroke prevention, it is
not recommended for elderly patients with HTN [141].
Concomitant use of beta-blockers and diuretics, which is
not inferior in its BP-lowering effect, will increase the in-
cidence of DM and should therefore be avoided in pa-
tients at high risk for developing DM [139]. Vasodilatory
beta-blockers might have different effects than atenolol,
but no comparative study has yet been performed to
date [142, 143].
Calcium channel blockers Long-acting calcium channel
blockers are preferable to short-acting calcium channel
blockers, which can cause tachycardia and increase car-
diac workload. Because calcium channel blockers have a
vasodilatory effect on the coronary artery, they are
highly effective in patients with stable angina or variant
angina, which is caused by coronary artery spasm. They
are also effective for slowing the progression of carotid
atherosclerosis and reducing cardiac hypertrophy [143].
The non-dihydropyridine calcium channel blockers, ver-
apamil, and diltiazem, are effective after myocardial in-
farction because they do not produce reflex tachycardia.
They are also effective in patients with hypertrophic car-
diomyopathy because they improve diastolic filling. The
common side effects of dihydropyridine calcium channel
blockers are tachycardia, ankle edema, headache, and
facial flushing. Non-dihydropyridine calcium channel





















Calcium channel blockers Elderly hypertension, isolate systolic







Diuretics Congestive heart failure, isolate systolic
hypertension
High blood glucose Gout, hypokalemia
*Non-DHP: non-dihydropyridine calcium channel blockers.
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blockers may cause constipation, conduction delay, and
decreased myocardial contractility and should therefore
be prescribed cautiously to patients with systolic heart
failure or heart block. In addition, special caution is
needed when administering them in combination with
beta-blockers in elderly patients.
Angiotensin converting enzyme inhibitors /
angiotensin receptor blockers ACE inhibitors/ARBs
reduce mortality in patients with heart failure and help
to inhibit the progression of renal disease. They also
help to prevent LVH and atherosclerosis and have little
effect on blood glucose or lipid metabolism [144]. In
addition, they can improve vascular endothelial cell
function and promote vascular reverse remodeling.
However, they can cause a hypotensive response in
dehydrated or elderly patients [145]. When administered
to a patient with bilateral renal artery stenosis, they can
produce adverse effects such as severe hypotension and
deterioration of renal function. The serum creatinine
level may increase within the first two months after the
start of treatment. However, there is no need to
discontinue the drug unless the serum creatinine
increases to less than 30% rise than the baseline
creatinine level or unless serum potassium is 5.5 mEq/L
or higher [146]. Care should be taken in patients with a
serum creatinine level higher than 3.0 mg/dL [147]. The
blood potassium level and renal function should be
checked before and within 1–4 weeks after
administration of the drug and then again three or six
months later. ACE inhibitors inhibit bradykinin
degradation and can thus cause a dry cough, but this
resolves within a few days to a few weeks after stopping
the medication. Dry cough is more common in women
and non-smokers. ARBs have no effect on bradykinin
and therefore rarely cause cough. ACE inhibitors/ARBs
are contraindicated in pregnant women because of their
teratogenic effects on the fetus.
Side effects include hyperkalemia, acute renal damage
in bilateral renal artery stenosis, abnormal taste,
leukopenia, angioedema, and rash.
Other agents Alpha-blockers can alleviate urinary
symptoms in patients with prostate enlargement and
also improve the metabolism of glucose and lipids.
However, they can cause orthostatic hypotension and are
associated with worsening of heart failure. Agents that
act on the central nervous system, such as clonidine,
methyldopa, and reserpine, have many side effects and
are therefore not recommended as first-line drugs. Renin
inhibitors have been developed and used in other coun-
tries but were not introduced in Korea. Renin inhibitors
significantly reduced BP and proteinuria when used
alone or in combination with diuretics. However,
aliskiren has not been proven to improve the prognosis
of patients with CVD. Methyldopa is still preferred for
the treatment of HTN in pregnant women but is not the
first choice because of its side effects. Hydralazine is a
vasodilator that is relatively safe for pregnant women
with HTN.
Combination therapy
More than 2/3 of patients with HTN require drugs from
more than two drug classes with different mechanisms
to achieve control of HTN. Combination therapy is
particularly helpful for patients receiving prolonged BP
treatment, high risk patients, and patients with lower
target BP. If the first drug used is not effective for BP
control, then a drug of another class should be tried. If
the efficacy is insufficient, the dose should be increased
or another drug added. However, it is recommended to
combine two different drugs in smaller doses rather
than to increase the dosage of one drug because such
low dose combinations lower BP more effectively and
improve the adherence while decreasing the adverse
effects (Fig. 3) [148]. In high risk HTN, the prognosis
can be improved as soon as BP is lowered below the
target. Therefore, we recommend the use of
combination therapy from the beginning in grade 2 or
high risk HTN [129]. In this case, single pill
combination can be considered as a first-line treatment
because it improves drug adherence [149]. However,
there is the disadvantage that the single pill combination
cannot control the drug dose freely when the side ef-
fect of the drug occurs. Since there is no direct com-
parative study with the existing combination
therapies, the choice of the single pill combination
may be determined by adherence, possible adverse ef-
fects, and the target BP.
If BP is not controlled with a single drug, two drugs
should be combined for BP control. Combination
therapy is more effective than single-drug therapy at a
higher dose [148]. However, it has not been fully
evaluated which combination is best. Combination
therapy chosen from the renin-angiotensin system in-
hibitors, calcium channel blockers, and diuretics is
recommended first because it has shown relatively
good results [58, 65, 150], but beta-blockers can also
be combined with drugs of other classes (Fig. 4).
However, the combination of beta-blockers and di-
uretics may increase the incidence of diabetes and
metabolic disorders and thus requires regular moni-
toring. Combination therapy with ARBs and ACE in-
hibitors may be slightly more effective for reducing
proteinuria but increases the risk for end-stage renal
failure, stroke, and other CVD, therefore is not re-
commended [151–153].
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Resistant hypertension
Recommendations Class Level References
•Examination of adherence and ambulatory
BP monitoring or home BP monitoring is
recommended to exclude pseudo-resistant
HTN.
I B [154]
• Addition of low-dose spironolactone can
be considered for the treatment of resistant
HTN.
IIa B [136]
Resistant HTN is defined as BP that cannot be
controlled (BP ≥140/90 mmHg) despite treatment with
more than three different classes of antihypertensive
drugs, including diuretics. The prevalence of resistant
HTN is reported to be 5–30% in other countries.
However, considering the frequency of pseudo-resistant
HTN, the prevalence of true resistant HTN is as-
sumed to be below 10%. Patients with resistant HTN
are at much higher risk for complications such as
CVD and CKD [155].
Fig. 4 Recommended combination therapy, thick lines; preferred combination, thin line; feasible combination
Fig. 3 Choice of single drug or combination drugs according to the level of blood pressure and the global cardiovascular risk
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Among the wide range of causes of resistant HTN
(Table 13), non-adherence is the most common. In
addition, medications taken for relief of cold symptoms,
non-steroidal anti-inflammatory drugs, adrenal cortical
steroids, birth control pills, excessive salt intake, and ex-
cessive alcohol consumption can also cause resistant
HTN. If diuretics have not been included in the regimen,
volume overload can cause resistant HTN. Finally, sec-
ondary HTN can cause resistant HTN.
To diagnose resistant HTN, treatment adherence should
be confirmed and then the home BP or ambulatory BP
should be monitored in order to exclude white coat HTN.
If BP cannot be controlled despite the use of effective doses
of three different classes of drug, then the dose of diuretics
should be increased, or thiazide diuretics changed to loop
diuretics in patients with renal impairment. However, most
patients with resistant HTN require a different mechanism
for BP control, and the fourth drug added should be
spironolactone, amiloride, or an alpha-blocker such as dox-
azosin [156–159]. When spironolactone or amiloride is
added in patients treated with ACE inhibitors or ARBs, the
blood potassium level should be checked within 1–2 weeks.
Device-based hypertension treatment
Carotid baroreceptor stimulation or renal denervation
may be tried in patients with true resistant HTN since
the risk of procedure-related complication is low. How-
ever, there are non-responders and a lack of evidence of
long-term effects, therefore it is not currently recom-
mended [160, 161].
Reduction or discontinuation of antihypertensive
medications
In patients whose BP has been well controlled for years,
or for an extended period, it may be possible to reduce
the number and/or dosage of drugs. This may
particularly be the case if BP control is accompanied by
healthy lifestyle changes such as weight loss, exercise
habits, and a low-fat and low-salt diet, which remove en-
vironmental pressor influences. A reduction of medica-
tions should be made gradually, and the patient should
be checked frequently, for example at least for three
months, because reappearance of HTN can occur fre-
quently [22].
Managing concomitant cardiovascular disease risk
The goal of antihypertensive therapy is to reduce the
overall CV risk in patients who have other risk factors
such as diabetes, dyslipidemia, CAD, stroke, and CKD.
Accordingly, these other risk factors should be treated
concurrently.
Antiplatelet therapy Aspirin administration has been
shown to produce an absolute benefit for the secondary
prevention of CVD in patients with HTN [162].
However, the role of aspirin for primary prevention
remains a matter of debate, leaning towards the negative
side. Low-dose aspirin (100 mg) can be prescribed to pa-
tients in high risk groups in order to reduce the risk of
CVD [162, 163]. Antiplatelet agents should be adminis-
tered after the BP is controlled, and patients should be
checked periodically for gastrointestinal bleeding.
Lipid-lowering agents Lipid-lowering agents have a
protective effect on high risk patients with HTN.
Although there is very little Korean data, a 50%
reduction in LDL-cholesterol in patients who had an
LDL-cholesterol level ≥ 130 mg/dL significantly lowered
the risk of CVD [164]. Lowering the LDL-cholesterol
level to < 70mg/dL should be recommended in patients
with CAD [165]. There is evidence for reducing the
LDL-cholesterol level to < 135 mg/dL in patients with
stroke [166], however, there is little data regarding the
effects of lowering the LDL-cholesterol to < 70 mg/dL in
such patients.
Glycemic control The goal of glycemic control in
patients with DM is less than 6.5% of glycated
hemoglobin, further lowering if there is no complication
associated with early diabetes and low risk of
hypoglycemia. Conversely, in patients with severe
hypoglycemia, short life expectancy, advanced
microvascular and macrovascular complications, and
elderly people over 75 years of age, the goal of glycemic
control can be individualized taking into account the
risk of hypoglycemia [167].





Calcified vessel in the elderly
(pseudohypertension)
Wrong cuff use, using too small cuff
Lifestyle factors Severe weight gain,
Heavy or binge drinking,
Sleep apnea syndrome
Volume overload Excess salt intake,
Volume expansion by renal diseases,
Insufficient use of diuretics
Medication Poor compliance,
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Patient monitoring and follow-up
Patients should generally be followed up once monthly,
at least until the target BP is achieved. Patients with
severe HTN (grade 2) require more frequent follow-up.
The serum potassium and creatinine levels should be
measured at least 1–2 times yearly. If the BP is con-
trolled and stable, then the patient should be followed
up every 3–6 months. A longer follow-up interval may
be associated with low adherence. Therefore, patient ad-
herence also must be monitored as well as the regular
follow up tests for blood samples. A longer follow-up
interval to monitor the status of BP control can be
achieved by encouraging home BP measurement.
Adherence
Trust between doctor and patient is the most important
issue in the treatment of HTN, and the patient should
therefore be encouraged to participate in the treatment
plan. Many patients may have obtained information
about various antihypertensive agents through various
routes, so discussion may be necessary. First, identify the
patient’s point of view to determine the relative
importance of efficacy, cost-effectiveness, and side ef-
fects. It is necessary to reduce overall CV risk as much
as possible while maintaining the patient’s adherence.
Self-measurement of BP by using HBPM can improve
adherence [5].
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